| Literature DB >> 27547627 |
Nikodem Kuźnik1, Mateusz Michał Tomczyk1.
Abstract
Magnetic resonance imaging (MRI) is one of the most commonly used tomography techniques in medical diagnosis due to the non-invasive character, the high spatial resolution and the possibility of soft tissue imaging. Contrast agents, such as gadolinium complexes and superparamagnetic iron oxides, are administered to spotlight certain organs and their pathologies. Many new models have been proposed that reduce side effects and required doses of these already clinically approved contrast agents. These new candidates often possess additional functionalities, e.g., the possibility of bioactivation upon action of particular stimuli, thus serving as smart molecular probes, or the coupling with therapeutic agents and therefore combining both a diagnostic and therapeutic role. Nanomaterials have been found to be an excellent scaffold for contrast agents, among which carbon nanotubes offer vast possibilities. The morphology of multiwalled carbon nanotubes (MWCNTs), their magnetic and electronic properties, the possibility of different functionalization and the potential to penetrate cell membranes result in a unique and very attractive candidate for a new MRI contrast agent. In this review we describe the different issues connected with MWCNT hybrids designed for MRI contrast agents, i.e., their synthesis and magnetic and dispersion properties, as well as both in vitro and in vivo behavior, which is important for diagnostic purposes. An introduction to MRI contrast agent theory is elaborated here in order to point to the specific expectations regarding nanomaterials. Finally, we propose a promising, general model of MWCNTs as MRI contrast agent candidates based on the studies presented here and supported by appropriate theories.Entities:
Keywords: carbon nanotube hybrids; contrast agent; magnetic resonance imaging (MRI); molecular probe; multiwalled carbon nanotubes (MWCNT); relaxation
Year: 2016 PMID: 27547627 PMCID: PMC4979685 DOI: 10.3762/bjnano.7.102
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Figure 1Transformations of MWCNTs. Only the final products subjected to relaxometric or MRI studies are presented in the figure with appropriate abbreviations. A - synthesis of MWCNTs with different catalysts, B - oxidation of MWCNTs with HNO3 (and in some cases with H2SO4), C - non-covalent SPIO introduction, D - covalent (and coordination) bonding of organic ligands, E - introduction (by coordination or other interactions) of metal species: ions, oxides, stem cells, F - non-covalent wrapping (X stands for a wrapping medium).
Figure 2Organic ligands in MWCNT hybrids.
Figure 3Structure of MWCNT hybrids.
Figure 4Relaxation enhancement of water protons by the MWCNT hybrid.
In vitro relaxivity of MWCNT hybrids.a
| MWCNT hybrid | % Fe | medium | ref. | ||||||||
| (mM·s)−1 | (mg/mL·s)−1 | (mM·s)−1 | (mg/mL·s)−1 | ||||||||
| 0.5–2.0/ | — | 12–50 | — | — | — | water | 0.5 | 25 | 1000 | [ | |
| 2–4 | 11.8 | ||||||||||
| — | — | — | — | — | — | — | 3 | — | — | [ | |
| 2.0/ | 2.6 | — | — | 564 | 260 | 1% agarose gel | 7.1 | 19 | 10–180 | [ | |
| — | 30 | — | — | 176 | 939 | water | 3.0 | rt | — | [ | |
| 0.5–2.0/ | 17 | 7 | 21 | 191 | 595 | water | 0.5 | — | — | [ | |
| — | — | 153 | 475 | 3.0 | |||||||
| — | — | 1 | — | 16 | — | water | 1.5 | — | — | [ | |
| 1.0/ | 1.3 | — | — | 489 | 110 | 1% Pluronic® F127 | 1.5 | — | 50–300 | [ | |
| 1.7 | — | — | 480 | 147 | |||||||
| 2.1 | — | — | 401 | 147 | |||||||
| 2.9 | — | — | 555 | 290 | |||||||
| 0.1–0.2/ | — | — | — | 264 | — | water | 3.0 | — | — | [ | |
| 1.5/ | — | 13 | — | 103 | — | water | 0.5 | 37 | — | [ | |
| 10.0/ | — | — | — | 186 | — | agarose gel | 3.0 | — | — | [ | |
| — | 15 | — | — | 425 | 1141 | 1% agarose gel, 0.5% Pluronic® F127 | 7.0 | — | — | [ | |
| 1.0/ | 2.2 | — | — | 102 | 40 | 1% SDBS solution in water | 0.4 | 37 | 63–1000 | [ | |
| 13 | — | — | 18 | 40 | |||||||
| 2.2 | 0 | 1 | 64 | 25 | 7.1 | 22 | |||||
| 13 | 0 | 0 | 15 | 35 | |||||||
| 0.4/ | 7.1 | 23 | 21 | 13 | 12 | water, agarose gel | 0.5 | 25 | — | [ | |
| 4 | 3 | 5 | 5 | 4.7 | |||||||
| 1.0/ | 13 | — | — | 18 | 41 | water | 7.1 | 22 | 50–500 | [ | |
| 16 | — | — | 22 | 64 | |||||||
| 6 | — | — | 52 | 58 | 1% SDBS solution in water | ||||||
| 1.0/29 | 1.6 | — | — | 130 | 36 | water | 0.4 | 37 | 6–300 | [ | |
| 1.0/49 | 2.3 | 165 | 69 | ||||||||
| 1.0/40 | 5.0 | 121 | 107 | ||||||||
| 1.0/29 | 1.6 | 136 | 38 | fetal bovine serum | |||||||
| 1.0/49 | 2.3 | 86 | 36 | ||||||||
| 1.0/40 | 5.0 | 110 | 98 | ||||||||
| 0.5/29 | 1.6 | 171 | 48 | water | |||||||
| 0.5/49 | 2.3 | 61 | 25 | ||||||||
| 0.5/40 | 5.0 | 44 | 39 | ||||||||
| 0.5/29 | 1.6 | 22 | 6 | fetal bovine serum | |||||||
| 0.5/49 | 2.3 | 24 | 10 | ||||||||
| 0.5/40 | 5.0 | 41 | 37 | ||||||||
| 1.0–10.0/ | — | — | — | 85 | — | — | 3.0 | — | — | [ | |
| — | — | 4.1 | — | 4.6 | — | water | 1.5 | — | 25 | [ | |
| — | — | 9.9 | — | 65 | — | water | 1.5 | — | — | [ | |
| — | — | — | — | 325 | — | 1% agarose gel, 0.5% Pluronic® F127 | 7 | — | — | [ | |
al/d: length/diameter, % Fe: iron content (m/m); r1 and r2: relaxivities (see Equation 1); B0: magnetic field during measurements, for 1H the frequency (in MHz) could be calculated by multiplication of the magnetic field with a factor of 42.5; T: temperature; C: concentration of MWCNT.
Figure 5Relaxivity evolution by transformations of iron complexes to SPIOs and forming MWCNT hybrids. The relaxivities in bold face type highlight the trend of an increasing r2 value.
Cytotoxicity of MWCNT hybrids.a
| MWCNT type | model | cell culture | viability (%) | time (h) | concentration (µg/mL) | ref. |
| hybrid | HEK 293T | 99, 30 | 24 | 2, 15 | [ | |
| reference | 99, 97 | |||||
| hybrid | MCF-7, L929 | 80 | 24–48 | 200 | [ | |
| hybrid | HeLa | 98, 80 | 24 | 25, 200 | [ | |
| L929 | 92, 84 | |||||
| hybrid | PC3 | 100 | 20 | 2–10 | [ | |
| reference | HEK 293 | 58 | 72 | 150 | [ | |
| Huh 7 Cell | 100 | |||||
| hybrid | HEK 293 | 100 | ||||
| Huh 7 | 99 | |||||
| 3.9% Fe | fibroblast | 84, 50, 41 | 24 | 5, 100, 600 | [ | |
| 5.8% Fe | 98, 67, 1 | |||||
| 12.4% Fe | 82, 51, 46 | |||||
| 3.9% Fe | HeLa | 100, 97, 73 | ||||
| 5.8% Fe | 97, 96, 59 | |||||
| 12.4% Fe | 100, 86, 53 | |||||
| hybrid | CHO-GFP | 94 | 72 | 200 | [ | |
| Huh 7 | 91 | |||||
aModel: results are given for a particulate MWCNT hybrid, in some cases results for a reference oMWCNT were provided, different iron content in oMWCTN#Maciejewska hybrids was investigated; viability: multiple values refer to different concentrations.
In vivo MRI contrast effect of the MWCNT hybrids.a
| complex | place | SI [%] | time | dose | ref. | |
| 7.1 | MSC | 77 ( | 5 days | 1 µg/mL | [ | |
| MSC | 106 ( | 1 µg/mL | ||||
| 3 | MCF-7 cells | 9 | 3 h | 100 µg/mL | [ | |
| 68 | 10 µg/mL | |||||
| 100 | 0 µg/mL | |||||
| liver, mice | 37 | 15–300 min | 2.5 mg/kg body | |||
| spleen, mice | 75 | |||||
| 3 | HeLa cells | 15 | 3 h | 100 µg/mL | [ | |
| 58 | 10 µg/mL | |||||
| 100 | 0 µg/mL | |||||
| 1.5 | tumor in mice grown from MDA-MB231 cells | 28 | 10 min | 100 µg per tumor | [ | |
| 19 | 1 day | |||||
| 15 | 7 days | |||||
| 3 | HeLa cells | 55 | 6 h | 0.08 mM Fe | [ | |
| 36 | ||||||
| 3 | intravenous injection, liver, mice | 31 | right after injection | 10 mg/kg body | [ | |
| intravenous injection, tumor, mice | 117 | |||||
| 3 | intravenous injection, liver, mice | 61 | right after injection | 100 mg/kg body | [ | |
| intravenous injection, tumor, mice | 93 | |||||
aSI: Signal intensity enhancement after injection.
List of abbreviations.
| abbreviation | |
| acac | acetylacetonate, 2,4-pentanodionate |
| CA | contrast agent |
| CNT | carbon nanotube |
| DTPA | diethylene triamine pentaacetic acid |
| FA | folic acid |
| Gly | glycine |
| GNT | gadonanotubes |
| Lac | lactose |
| LBL | layer by layer |
| MSC | mesenchymal stem cells |
| MWCNT | multiwalled carbon nanotube |
| MRI | magnetic resonance imaging |
| NMR | nuclear magnetic resonance |
| PAH | poly(allylamine hydrochloride) |
| PDDA | poly(diallyldimethylammonium chloride) |
| PEI | polyethylenimine |
| PEG | poly(ethylene glycol) |
| PMETAC- | poly[2-(methacryloyloxy)ethyltrimethylammonium chloride]- |
| Pol | poloxamer, nonionic triblock copolymers, e.g. Pluronic® |
| PSS | polystyrene sulfonate sodium salt |
| SDBS | sodium dodecylbenzenesulfonate |
| SPIO | superparamagnetic iron oxide |
| SWCNT | single-walled carbon nanotube |